Health care spending associated with preventative pharmacologic therapy for urolithiasis.
Sign Up to like & getrecommendations! Published in 2025 at "Urology practice"
DOI: 10.1097/upj.0000000000000829
Abstract: INTRODUCTION Urolithiasis is among the most expensive urologic conditions from a payer standpoint. Preventative pharmacologic therapy (PPT) can reduce symptomatic recurrences, however, the potential savings from fewer recurrences may be offset by medication costs. This… read more here.
Keywords: preventative pharmacologic; urolithiasis; spending; therapy ... See more keywords